SymphoRNA key facts
- Operator of a novel cultivated-protein production process designed to create animal-cell-derived meat without conventional livestock.
- SymphoRNA’s last known valuation is $98.4M.
- It has raised $49.2M; the latest was Later Stage VC ($13.2M) in Nov 2024.
- Notable investors include Global Brain, MicroVentures, Lowercarbon Capital, Balderton Capital, Redalpine — 22 tracked in total.
- Status: Privately Held (backing).
Who backs SymphoRNA
22+Membership and data by Private Market View
- ·The complete investor list: 22 names
- ·Watch SymphoRNA: the Monday email on marks, rounds and moves
SymphoRNA funding rounds
No funding rounds for SymphoRNA are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
SymphoRNA valuation
SymphoRNA's last known valuation is $98.4 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
SymphoRNA investors
22 investors are on record for SymphoRNA, including Global Brain, MicroVentures, Lowercarbon Capital and Balderton Capital. By type, the record holds 5 venture capital firms and 1 hedge fund.
About SymphoRNA
Operator of a novel cultivated-protein production process designed to create animal-cell-derived meat without conventional livestock. The company offers an RNA-based reprogramming technology along with non-GMO cell-engineering and scalable pilot manufacturing, enabling food producers and ingredient manufacturers to bring meat products to market more efficiently.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2017
- Employees
- 11
- Website
- symphorna.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
SymphoRNA’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.